Details

Autor(en) / Beteiligte

• Said, Kamaleldin B
• Alsolami, Ahmed
• Alreshidi, Fayez Saud
• Fathuddin, Anas
• Alshammari, Fawwaz
• Alrashid, Fauwaz
• Aljadani, Ahmed
• Aboras, Rana
• Alreshidi, Fatmah
• Alghozwi, Mohammed H
• Alshammari, Suliman F
• Alharbi, Nawaf F

Titel

Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals

Ist Teil von

• Journal of multidisciplinary healthcare, 2023-01, Vol.16, p.1215-1229

Ort / Verlag

New Zealand: Dove Medical Press Limited

Erscheinungsjahr

2023

Quelle

Taylor & Francis Journals

Beschreibungen/Notizen

• The lack of feasible therapies and comorbidities aggravate the COVID-19 case-fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant cardiovascular diseases, chronic kidney disease, and chronic liver disease (CLD) are limited. More studies assessing hydroxychloroquine (Hcq) and antivirals are needed. To examine associations of COVID-19 CFR in comorbid patient groups each with single comorbidities and after treatment with Hcq, favipiravir, and dexamethasone (Dex), either alone or in combination versus standard care. Using statistical analysis, we descriptively determined these associations among 750 COVID-19 patient groups during the last quarter of 2021. A diabetes comorbidity (40%, n=299) showed twice the fatality (CFR 14%) of the others (CFR 7%; =0.001). Hypertension (Htn) was the second-commonest comorbidity (29.5%, n=221), with similar CFR to diabetes (15% and 7% for Htn and non-Htn, respectively), but with higher significance ( =0.0006167). Although only 4% (n=30) heart failure (HF) was reported, the CFR (40%) was much higher than in those without it (8%). A similar rate (4%) for chronic kidney disease was reported, with CFRs of 33% and 9% among those with and without it, respectively ( =0.00048). Ischemic heart disease was 11% (n=74), followed by chronic liver disease (0.4%) and history of smoking (1%); however, these were not significant due to the sample sizes. Treatment indicated standard care and Hcq alone or in combination were superior (CFR of 4% and 0.5%, respectively) compared to favipiravir (25%) or Dex (38.5%) independently or in combination (35.4%). Furthermore, Hcq performed well (CFR 9%) when combined with Dex (9%; =4.28- ). The dominance of diabetes and other comorbidities with significant association with CFR implied existence of a common virulence mechanism. The superiority of low-dose Hcq and standard care over antivirals warrants further studies.